ECI Biotech is awarded mentorship in the 2010-2011 NIH SBIR Commercialization Assistance Program (CAP) for a second year.

October 8, 2010 - ECI Biotech, an innovative developer of diagnostic sensors that will ultimately transform the way pathogens are detected in professional and OTC markets has been selected to participate in the 2010-2011 National Institute of Health (NIH) SBIR Commercialization Assistance Program (CAP).  ECI Biotech has been assigned to the Accelerator Commercialization Track (ACT).  This will be ECI Biotech’s second year participating in the program.

The NIH CAP is a specialized technical assistance program for SBIR Phase II awardees.  CAP is designed to help promising small life science companies develop their commercialization businesses and transition their SBIR–developed technologies into the marketplace. 

The goal of the ACT mentorship program is to target the most critical issues a company has pertinent to any who have successfully commercialized (or sold) products and/or services, generated revenue, established partnerships and/or otherwise achieved a level of market development that is sustainable over a definitive period. It is designed to create a desired commercialization outcome that will best position a company to successfully move its SBIR-developed product into the marketplace.

Funded by NIH and managed through a contract with Larta Institute (www.larta.org) of Los Angeles, CA, the CAP provides selected participants with individualized assistance toward accomplishing their commercialization goals.  This is achieved through training workshops and individual mentoring and consulting sessions.

Dr. Mitchell Sanders, the CEO and Founder of ECI Biotech, said, “ECI Biotech has been chosen to participate in this very prestigious mentoring program for the second year in a row.  Participating in the NIH CAP will help us to accelerate our quality systems and submit clinical data for regulatory approval. We are very excited to move our SBIR Phase II status to the next level in order to get our diagnostic sensors out into the marketplace for both point-of-care (PoC) professional use, as well as consumer OTC markets.”

ECI Biotech has a broad bacterial detection capability that has implications in the diagnosis and treatment of rapid infections.  Our infection sensor diagnostics can be incorporated into any medical device or consumer product and will ultimately transform the way pathogens are detected in wound care, women's health, baby care and oral care.

^top